Spencer Knight: That's what I'm saying. I see both sides. If Contrave makes it to market it will be great for OREX. Still ARNA's approval is bad for OREX.
6/27/12
•!Report Abuse
Adam Gefvert: Then Qnexa will get approved. By the time Contrave gets approved, there's no more market share.
Spencer Knight: That's what I've been saying about lorcaserin as well. If qnexa is approved it will take away some of lorcaserin's luster.
6/27/12
•!Report Abuse
FortSumter: Shorted OREX via July $4.50 put. Doesn't seem rational to compare biotechs as equal trades like retail or oil stocks.
6/27/12
•!Report Abuse
Maria Auziliadora: Spencer that's why I think ARNA didn't fly to crazy levels because we still have Qnexa in the horizon One thing though VVUS stock is high!!